Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Since Abcam's acquisition in 2023, founder Jonathan Milner has been making waves with his investment strategy. Discover his ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...